Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is an immuno-pharma company with potential catalysts for stock growth in the form of positive clinical data from ongoing trials, strong partnerships with major research centers for multiple cancer treatments, and an attractive current valuation with a high upside potential and enough cash to sustain the company for the next few years. Due to the long development time and potential risks, it is important for investors to consider the company's balance sheet and potential regulatory and commercialization challenges, but the positive data from recent clinical studies and regained stock listing present promising signs for future success.

Bears say

AIM ImmunoTech is an early-stage drug company that generates a high net loss, with a $4.2 million net loss in Q4 2025 and no guidance for future financials. While maintaining a BUY rating, the financial analyst has lowered their price target to $22 due to significant balance sheet/liquidity risks and potential failure of product candidates in clinical trials. These risks, along with competition, macroeconomic factors, and changing priorities in healthcare, could impact investor sentiment and the company's ability to commercialize its products and gain suitable reimbursement, making the overall outlook negative.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.